Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
9
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,516.50 | 4.60 | 0.05% |
| CAC 40 | 7,445.69 | 163.47 | 2.24% |
| DAX 40 | 20,216.19 | 310.11 | 1.56% |
| Dow JONES (US) | 42,706.56 | 25.57 | -0.06% |
| FTSE 100 | 8,249.66 | 25.68 | 0.31% |
| HKSE | 19,688.29 | 71.98 | -0.36% |
| NASDAQ | 19,864.98 | 243.30 | 1.24% |
| Nikkei 225 | 39,307.05 | 587.49 | -1.47% |
| NZX 50 Index | 13,026.30 | 46.63 | -0.36% |
| S&P 500 | 5,975.38 | 32.91 | 0.55% |
| S&P/ASX 200 | 8,257.40 | 6.90 | 0.08% |
| SSE Composite Index | 3,206.92 | 4.51 | -0.14% |